Cargando…
伴有EGFR突变的非小细胞肺癌血清CYFRA21-1和CEA水平与EGFR-TKIs的疗效关系
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment regimen for EGFR mutated non-small cell lung cancer (NSCLC) patients.However, the efficacy of EGFR-TKIs widely varies.The aim of this study is to determine whether...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972987/ https://www.ncbi.nlm.nih.gov/pubmed/27561807 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.12 |